| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.1 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.29 | 0.1 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |